Short-term effect of thymosin al combined with MVP chemotherapy on quality of life in patients with non-small cell lung
10.3760/cma.j.issn.1008-6315.2009.11.015
- VernacularTitle:胸腺肽α1联合MVP方案化疗对非小细胞肺癌患者近期生存质量的影响
- Author:
Dejie CHU
;
Yong DU
;
Shuigen GUO
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
MVP Protocol;
Thymosin α1
- From:
Clinical Medicine of China
2009;25(11):1160-1161
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of thymosin and MVP chemotherapy on the life quality of non-small cell lung cancer(NSCLC) patients. Methods 50 cases of NSCLC patients who received MVP(MMC, VDS, DDP) chemotherapy,were randomly divided into experimental group (using thymosin α1) and control group;before chemotherapy and at the end of chemotherapy (the first 2 weeks), the quality of life was evaluated and analyzed comparatively by the FACT-L questionnaire of patients with lung cancer-Chinese version (V4.0). Results The re-sults of the experimental group score increased by (3.13±2.29),and control group score increased by(-1.07± 2.19) with significant differences (P<0.01). Conclusions Thymosin α1 can improve the short-term quality of life of the non-small cell lung cancer patients who received MVP chemotherapy.